DexCom, Inc.
Financials
Valuation Metrics
DexCom, Inc.'s Market Cap is $33.69B. At end of 2025 it was $25.67B. Ranked #426 of 3,112 in US market (top 14%), #126 of 1,445 on NASDAQ (top 9%), #26 of 206 in Health Care Equipment & Services (top 13%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $33.69B | US#426/3,112 Sec#26/206 |
| Revenue | $4.97B | US#905/3,112 Sec#51/206 |
| Net Income | $1000M | US#531/3,112 Sec#30/206 |
| Total Assets | $6.46B | US#1,253/3,112 Sec#56/206 |
| Net Assets | $2.62B | US#1,072/3,112 Sec#55/206 |
| Employees | 11,000 | US#562/3,112 Sec#52/206 |
| Value | ||
| P/E | 33.70x | US#1,562/3,112 Sec#60/206 |
| P/B | 12.85x | US#2,689/3,112 Sec#181/206 |
| PEG | 0.87x | US#780/3,112 Sec#29/206 |
| P/S | 6.78x | US#2,482/3,112 Sec#174/206 |
| EV/EBITDA | 23.99x | US#2,021/3,112 Sec#101/206 |
| FCF Yield | 4.17% | US#1,476/3,112 Sec#81/206 |
| Profitability | ||
| ROE | 38.14% | US#182/3,112 Sec#10/206 |
| ROA | 15.49% | US#196/3,112 Sec#10/206 |
| Op. Margin | 22.92% | US#755/3,112 Sec#23/206 |
| Revenue Growth | 13.08% | US#1,071/3,112 Sec#74/206 |
| Earnings Growth | 38.54% | US#650/3,112 Sec#28/206 |
| Financial Health | ||
| Debt Ratio | 146.25% | US#1,469/3,112 Sec#136/206 |
| Total Debt | $1.35B | US#1,328/3,112 Sec#71/206 |
| FCF | $1.41B | US#459/3,112 Sec#30/206 |
| Cash | $1.10B | US#635/3,112 Sec#33/206 |
| Current Ratio | 1.73x | US#1,452/3,112 Sec#129/206 |
| Net Debt/EBITDA | 0.17x | US#702/3,112 Sec#44/206 |
| Performance | ||
| 1Y Return | 10.13% | US#1,624/3,112 Sec#114/206 |
| 1M Return | 22.54% | US#108/3,112 Sec#17/206 |
| From 52W High | -0.37% | US#42/3,112 Sec#1/206 |
| 1Y MDD | -38.75% | US#1,890/3,112 Sec#100/206 |
| Trading | ||
| Volume | 8,779,598 shares | US#196/3,112 Sec#5/206 |
| Trading Value | $756M | US#135/3,112 Sec#6/206 |
| Per Share | ||
| EPS | $2.16 | US#1,215/3,112 Sec#63/206 |
| BPS | $7.10 | US#2,030/3,112 Sec#120/206 |
Company Info
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.